2023-01-25 21:05:00

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

Logo GlobeNewswire
GlobeNewswire

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117. The known information has been reported to the U.S. Food and Drug Administration (FDA) as a Suspected Unexpected Serious Adverse Reaction (SUSAR). After consultation with the trials safetyCohort Review Committeeand with the highest regard for patient safety, Magenta has voluntarily paused dosing in the clinical trial and is working to evaluate the totality of available data and determine next steps for the development of MGTA-117.

About Magenta Therapeutics
Magenta Therapeuticsis a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize blood and immune reset to allow more patients to take advantage of the curative potential of stem cell transplant and potentially improve eligibility for future gene therapies.

Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. These statements include, without limitation, implied and express statements relating to: Magenta working to evaluate the totality of available data and determine next steps for the development of MGTA-117.

Words such as anticipate, believe, continue, could, designed, endeavor, estimate, expect, intend, may, might, plan, potential, predict, project, seek, should, target, preliminary, will, would and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: volatility and uncertainty in the capital markets for biotechnology companies; uncertainties inherent in preclinical and clinical trials and in the availability and timing of data from ongoing and planned clinical and preclinical trials; the ability to initiate, enroll, conduct or complete ongoing and planned preclinical and clinical trials; vulnerability and/or fragility of, and the presence of underlying disorders in, the patient population for the clinical trials of Magentas product candidates, including the MGTA-117 Phase 1/2 clinical trial in patients with relapsed/refractory AML and MDS; that preliminary data from Magentas clinical trials may change materially following a more comprehensive review of the data; the delay of any current or planned preclinical or clinical trials, or the delay in development of Magentas product candidates; whether results from preclinical or earlier clinical trials will be predictive of the results of future trials; interactions with regulatory agencies such as the U.S. Food and Drug Administration; the expected timing of submissions for regulatory approval to conduct or continue trials or to market products; Magentas ability to successfully demonstrate the safety and efficacy of its product candidates; whether Magentas cash resources will be sufficient to fund Magentas foreseeable and unforeseeable operating expenses and capital expenditure requirements; and risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, preclinical activities, clinical trials, strategy, goals and anticipated timelines. These and other risks are described in additional detail in Magentas Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and its other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release represent Magentas views only as of today and should not be relied upon as representing its views as of any subsequent date. Magenta explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

Contact:
investor@magentatx.com


Continue read on globenewswire.com

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 11:50:00
Merck MRK, known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYNOTE-991 trial investigating KEYTRUDA,...

Logo PR Newswire
HealthPress Release2023-01-25 17:40:00
Patients living with myasthenia gravis (MG) provide their health and symptom experience data in a safe, secure registry to drive new research and discoveries...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 17:40:00
Patients living with myasthenia gravis (MG) provide their health and symptom experience data in a safe, secure registry to drive new research and discoveries...

Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...

Logo PR Newswire
HealthPress Release2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 11:45:00
Merck MRK, known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 KEYNOTE-966 trial. In the final analysis...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage...

Logo Benzinga
Business / FinanceBy Lara Goldstein2023-01-25 19:55:10
Short-acting psychedelics biotech Small Pharma Inc. DMTTFs proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-25 13:14:19
(RTTNews) - Tango Therapeutics, Inc. (TNGX) Wednesday announced FDA clearance for its Investigational New Drug or IND application for TNG462, a...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc....

Logo Daily Mail
HealthBy Kate Pickles2023-01-25 12:09:36
A new drug is set to transform the lives of thousands of migraine sufferers after it was approved for use on the NHS. The National Institute for Health and...

Logo PR Newswire
HealthPress Release2023-01-25 13:27:00
Patient Recruitment Underway NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company,...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 14:55:00
This legislation is expected to create more demand for GATC's drug discovery and development platform as AI and machine learning are increasingly used in...

Logo PR Newswire
HealthPress Release2023-01-25 13:00:00
Features new highlights and rankings of the top 50 drug classes by percent of net spend EAGAN, Minn., Jan. 25, 2023 /PRNewswire/ -- Magellan Rx Management...

Logo BBC
HealthBy Https://Www Facebook Com/Bbcnews2023-01-25 14:38:41
An experimental cancer treatment initiative is to get a 3m funding boost to trial new drugs and therapies. Manchester Experimental Cancer Medicine Centre...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 23:55:27
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...

Logo PR Newswire
HealthPress Release2023-01-25 13:05:00
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in...

Logo GlobeNewswire
HealthPress Release2023-01-25 12:00:00
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase Technologies Inc. ( Theralase or the Company ) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage...